Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
Metrics: PDF 1234 views | ?
1Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan
2Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan
3Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan
4Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Nagano, 390-8510, Japan
5Department of Surgery, Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan
6Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-0815, Japan
7Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Kitakyusyu, Fukuoka, 806-8501, Japan
8Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan
9Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Shinagawa-Ku, Tokyo, 142-8666, Japan
10Division of Clinical Oncology, Jichi Medical University, Shimotsuke-Shi, Tochigi, 329-0498, Japan
11Gastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, 655-0031, Japan
12Department of Surgery, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, 040-8611, Japan
13Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Osaka, 569-8686, Japan
14Department of Clinical Medicine (Biostatistics), Kitasato University School of Pharmacy, Minato-ku, Tokyo, 108-8641, Japan
15Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan
15Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, 227-8501, Japan
*These authors have contributed equally to this work
Published: July 06, 2018
This article has been corrected: The corrected author name is given below:
Original article: Oncotarget. 2018; 9:18811-18820. DOI: https://doi.org/10.18632/oncotarget.24702.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.